Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

The oral PI3Kdelta inhibitor Linperlisib and Obinutuzumab as response-dependent, first-line regimen for marginal zone lymphoma: A prospective single-arm Phase Ib/II Study

Jia Li, Xingtong Wang, Wei Guo, Yangzhi Zhao, chunshui liu, Ou Bai

Blood (2025) 146 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2025-7099

Published: 2025

Journal Articles

Concurrent viral infection as an adverse prognostic factor in diffuse large B-cell lymphoma, not otherwise specified

Haotian Wang, Jia Li, Luming Cao, Xingtong Wang, Ying Zhang, Xin Wan, Chengqian Chen, Zhaoxia Li, Jihong Xu, Yueyue Wen, Panpan Yan, Yang Song, Ou Bai

Blood (2025) 146 (Supplement 1): 3668.

https://doi.org/10.1182/blood-2025-3668

Published: 2025

Journal Articles

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Blood (2025) 146 (Supplement 1): 7583.

https://doi.org/10.1182/blood-2025-7583

Published: 2025

Journal Articles

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study

Wei Guo, Yangzhi Zhao, Jia Li, Xingtong Wang, chunshui liu, Junna Li, Ou Bai

Blood (2025) 146 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2025-1921

Published: 2025

Journal Articles

Characteristics, treatment outcomes, and prognostic analysis of 118 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia

Yangzhi Zhao, wei Guo, Jia Li, Xingtong Wang, junna Li, chunshui liu, Ou Bai

Blood (2025) 146 (Supplement 1): 3608.

https://doi.org/10.1182/blood-2025-3608

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Comparative efficacy and safety of obinutuzumab- versus rituximab-based immunochemotherapy in newly diagnosed burkitt lymphoma: A single-center retrospective study

Ying Zhang, Wei Guo, Haotian Wang, Luming Cao, Jihong Xu, Xin Wan, Jia Li, Zhumei Zhan, Rui Xing, Ou Bai

Blood (2025) 146 (Supplement 1): 6886.

https://doi.org/10.1182/blood-2025-6886

Published: 2025

Journal Articles

Efficacy and safety of rituximab, high-dose methotrexate, and thiotepa (R-MT) as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma

Haotian Wang, Jia Li, Xingtong Wang, Luming Cao, Chengqian Chen, Xin Wan, Ying Zhang, Zhaoxia Li, Jihong Xu, Panpan Yan, Yueyue Wen, Yang Song, Ou Bai

Blood (2025) 146 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2025-5475

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor injection (PEG-rhG-CSF) in autologous hematopoietic stem cell mobilization for lymphoma - Results of interim analysis

Wei Guo, Yangzhi Zhao, Jia Li, Xingtong Wang, Junna Li, chunshui liu, Ou Bai

Blood (2025) 146 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2025-2408

Published: 2025

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Agnish Dey, Jia Li, Jae H. Park, Leopold Sellner, Varsha Sundaresan, Maria Lia Palomba, Jorge Mansilla-Soto, Brigitte Senechal, Xiuyan Wang, Devanjan S Sikder, Ajeeta Dash, Isabelle Riviere, Michel Sadelain, Ganesh Mugundu

Blood (2024) 144 (Supplement 1): 7138.

https://doi.org/10.1182/blood-2024-203375

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Yuqin Song, Ningjing Lin, Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinna Ma, Miao Hu, Yanping Zhang, Jia Li, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2024-200544

Published: 2024

Journal Articles

The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma

Xingtong Wang, Wei Guo, Yangzhi Zhao, Jia Li, Ou Bai

Blood (2024) 144 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2024-206302

Published: 2024

Journal Articles

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Ying Zhang, Wei Guo, Yangzhi Zhao, Zhumei Zhan, Haotian Wang, Zhe Li, Bowen Wang, Luming Cao, Xin Wan, Jia Li, Ou Bai

Blood (2024) 144 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2024-204677

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

Huinan Jiang, Xianming He, Qing Leng, Miao Miao, Ming Zhang, Yingchun Li, Guojun Zhang, Jia Li, Rong Zhang, Ying Lv, Zhuogang Liu, Fei Tian, Rong Li, Wenxia Liu, Rui Zhang, Xiaohong Wang, Aijun Liao

Blood (2024) 144 (Supplement 1): 7081.

https://doi.org/10.1182/blood-2024-201906

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Luo, Jonathan How, John M. Storring, Gizelle Popradi

Blood (2024) 144 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2024-198536

Published: 2024

Journal Articles

Exploration of Rituximab Plus Lenalidomide（R 2 ）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy

Jia Li, Ou Bai, Yangzhi Zhao, Wei Guo, Xingtong Wang

Blood (2024) 144 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2024-204951

Published: 2024

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The oral PI3Kdelta inhibitor Linperlisib and Obinutuzumab as response-dependent, first-line regimen for marginal zone lymphoma: A prospective single-arm Phase Ib/II Study

Concurrent viral infection as an adverse prognostic factor in diffuse large B-cell lymphoma, not otherwise specified

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study

Characteristics, treatment outcomes, and prognostic analysis of 118 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Comparative efficacy and safety of obinutuzumab- versus rituximab-based immunochemotherapy in newly diagnosed burkitt lymphoma: A single-center retrospective study

Efficacy and safety of rituximab, high-dose methotrexate, and thiotepa (R-MT) as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor injection (PEG-rhG-CSF) in autologous hematopoietic stem cell mobilization for lymphoma - Results of interim analysis

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Efficacy and Safety of Daratumumab Combined with Bortezomib and Dexamethasone Regimen in Newly-Diagnosed Multiple Myeloma Patients

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Exploration of Rituximab Plus Lenalidomide（R 2 ）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only